Ok - perhaps I should have said paracrine instead of the intracellular. My bad. Of course we know the observed effects on epithelial and endothelial cells. Not to mention the good work with TNF-α and IL-6.
My point remains, MSB need not be pumped. Leave that for those out of the ASX200, like drug re-purposers and the like.
Countdown to Interim Analysis, page-142
-
- There are more pages in this discussion • 54 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
-0.110(8.43%) |
Mkt cap ! $1.364B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.30 | $1.17 | $11.89M | 9.659M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 7478 | $1.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 50270 | 21 |
View Market Depth
| Last trade - 11.58am 24/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |